A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy.
复制标题

DOI:
10.1038/cddis.2010.18
复制
发表时间:
2010-05-06
影响因子:
9
通讯作者:
--
中科院分区:
生物学1区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

我们使用qPCR技术研究了68种人类癌细胞系中所有6种抗凋亡Bcl-2亚家族成员的mRNA表达水平,并测量了已知Bcl-2抑制剂在36种研究的肿瘤细胞系中诱导细胞死亡的能力。我们的研究表明,Mcl-1代表抗凋亡Bcl-2亚家族成员,在肺癌、前列腺癌、乳腺癌、卵巢癌、肾癌和神经胶质瘤细胞系中具有最高的mRNA水平。在白血病/淋巴瘤和黑色素瘤癌细胞系中,Bcl-2和Bfl-1分别具有最高水平的mRNA。所观察到的已知Bcl-2抑制剂的细胞杀伤特性与抗凋亡Bcl-2蛋白的相对mRNA表达水平之间的相关性为靶向Bcl-2蛋白的基于凋亡的抗癌策略提供了重要见解。我们的数据可以解释目前的挑战,选择性Bcl-2抑制剂在临床上,考虑到Bcl-2的严重表达似乎仅限于白血病细胞系。此外,我们的数据表明,在大多数癌症类型中,靶向Mcl-1抑制或Bfl-1和Mcl-1联合抑制黑色素瘤的策略可能比仅靶向Bcl-2的疗法更成功。
We investigated the mRNA expression levels of all six antiapoptotic Bcl-2 subfamily members in 68 human cancer cell lines using qPCR techniques and measured the ability of known Bcl-2 inhibitors to induce cell death in 36 of the studied tumor cell lines. Our study reveals that Mcl-1 represents the anti-apoptotic Bcl-2 subfamily member with the highest mRNA levels in the lung, prostate, breast, ovarian, renal, and glioma cancer cell lines. In leukemia/lymphoma and melanoma cancer cell lines, Bcl-2 and Bfl-1 had the highest levels of mRNA, respectively. The observed correlation between the cell killing properties of known Bcl-2 inhibitors and the relative mRNA expression levels of anti-apoptotic Bcl-2 proteins provide critical insights into apoptosis-based anticancer strategies that target Bcl-2 proteins. Our data may explain current challenges of selective Bcl-2 inhibitors in the clinic, given that severe expression of Bcl-2 seems to be limited to leukemia cell lines. Furthermore, our data suggest that in most cancer types a strategy targeted to Mcl-1 inhibition, or combination of Bfl-1 and Mcl-1 inhibition for melanoma, may prove to be more successful than therapies targeting only Bcl-2.
DOI: 10.1073/pnas.0701297104
发表时间: 2007-04-10
影响因子: 11.1
作者:
Czabotar, Peter E.;Lee, Erinna F.;Colman, Peter M.
通讯作者: Colman, Peter M.
DOI: 10.1073/pnas.041619798
发表时间: 2001-03-13
影响因子: 11.1
作者:
Petros, AM;Medek, A;Fesik, SW
通讯作者: Fesik, SW
DOI: 10.1038/sj.bjc.6603359
发表时间: 2006-11-06
影响因子: 8.8
作者:
Maruyama, R.;Yamana, K.;Tomita, Y.
通讯作者: Tomita, Y.
DOI: 10.1200/jco.2006.07.1191
发表时间: 2007-03-20
影响因子: 45.3
作者:
O'Brien, Susan;Moore, Joseph O.;Rai, Kanti R.
通讯作者: Rai, Kanti R.
DOI: 10.1097/00008390-199806000-00001
发表时间: 1998-06-01
期刊: MELANOMA RESEARCH
影响因子: 2.2
作者:
Selzer, E;Schlagbauer-Wadl, H;Jansen, B
通讯作者: Jansen, B